Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Inclusion Criteria: * Age from 18 to 64 years old for the pre inclusion visit. * Documented HIV-1 Infection * Preferentially, group A patients from CDC classification but no group C patients. * HIV-1 patients treated with three antiretroviral drugs since 12 months not changed since three months and having an undetectable viremia since 12 months. * HIV-1 Chronic infection defined by a positive HIV-1 ELISA and HIV-1 proteins characterized in a full HIV-1 Western blot. Stable undetectable plasmatic HIV RNA (lower than 40 copies/ml) since 12 months. Lymphocyte CD4 cells higher than 350/mm3 with a NADIR higher than 200/mm3 since 12 months. * Free engagement, fully explained and wrote with the patient signature for the inclusion visit and before any test required for the clinical trial. * Patient affiliated to a social security system. * No vaccination against influenza or other pathogens since three months. * No chemotherapy or treatments with corticosteroid * HIV-1 patients being abstinent former drug users or drug users following substitution training. Exclusion Criteria: * HIV-1 patient protected regarding French law (articles L1121-5, L1121-6, L1121-7, L1121-8 \& L1122-2) * No HIV-1 infection * Patient infected with HIV-2 * Patient in HIV-1 primo infection or recently in primo infection * Patient in symptomatic primo infection or CD4 cells lower than 200/mm3 * Women sexually active with no efficient contraception * Pregnant women or brass feeding. * Patient with an opportunistic infection in the CDC group C. * Patient with a cancer and/or under chemotherapy or radiotherapy. * Patient with an evolutive psychiatric pathology * Patient being HBV and/or HCV positive * Patient being ELISA positive for HTLV-1 * Patient being cirrhotic (Child and Pugh level A, B and C) * Patient under criminal investigation * Patients with abnormal blood formulation * Patient participating to another clinical research